EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Efficacy of Dienogest for Symptomatic Adenomyosis

Yejin Kwon, Ju Hee Kim iD, Hee Dong Chae iD, Sa Ra Lee iD, Sung Hoon Kim iD

Journal of Clinical Medicine · 06.04.2026 · 15 (7) · 2763

DOI: 10.3390/jcm15072763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.04.2026. Verfasst von Yejin Kwon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-Ro 43-GIL, Songpa-gu, Seoul 05505, …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study was conducted to assess whether medical treatment with dienogest (DNG) is effective in women with symptomatic adenomyosis.

Methods

This single-center, retrospective study included patients with symptomatic adenomyosis treated with oral DNG 2 mg daily. We evaluated the clinical symptoms, uterine volume, and serum CA-125 levels in these patients along with adverse events at baseline and after 3, 6, 12, 18, and 24 months of treatment, respectively.

Results

A total of 102 patients were analyzed. Among women with dysmenorrhea, 79.5% reported improvement in dysmenorrhea, and the mean time to improvement in dysmenorrhea was 7.18 months. Improvement in heavy menstrual bleeding was observed in 88.3% of patients, with a mean time to improvement in heavy menstrual bleeding of 5.44 months. We could see that the uterine volume decreased significantly after 18 months of treatment. Serum CA-125 levels declined significantly from 3 months onward and remained reduced through 24 months. More than half of the patients (55.8%) continued DNG without complications, whereas 31.3% discontinued treatment or switched to alternative therapies.

Conclusions

DNG effectively improved clinical symptoms and reduced uterine volume and serum CA-125 levels without serious adverse events in patients with symptomatic adenomyosis.

Schlagwörter

Stichwörter der Autor:innen

CA-125adenomyosisdienogestendometriosismedical treatment

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-Ro 43-GIL, Songpa-gu, Seoul 05505, Republic of Korea.

ORCID-Profile: Ju Hee Kim, Hee Dong Chae, Sa Ra Lee, Sung Hoon Kim

Förderung

  • Ministry of Science and ICT

Zitieren

APA

Kwon, Y., Kim, J. H., Chae, H. D., Lee, S. R., & Kim, S. H. (2026). Clinical Efficacy of Dienogest for Symptomatic Adenomyosis. Journal of Clinical Medicine, 15(7), 2763. https://doi.org/10.3390/jcm15072763

Vancouver

Kwon Y, Kim JH, Chae HD, Lee SR, Kim SH. Clinical Efficacy of Dienogest for Symptomatic Adenomyosis. Journal of Clinical Medicine. 2026;15(7):2763. doi:10.3390/jcm15072763

BibTeX
@article{Kwon2026,
  author = {Kwon, Yejin and Kim, Ju Hee and Chae, Hee Dong and Lee, Sa Ra and Kim, Sung Hoon},
  title = {Clinical Efficacy of Dienogest for Symptomatic Adenomyosis},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {2763},
  doi = {10.3390/jcm15072763}
}
Kostenlos starten →